• What is CMT?
    • About CMT
    • Type1
      • What is CMT1A?
      • What is CMT1B?
      • What is CMT1E?
      • What is HNPP?
    • Type2
      • What is CMT2A?
    • Type4
      • What is SORD?
    • TypeX
      • Understanding CMT1X/CMTX1 and GJB1
    • —-
    • Watch Our Video Series
    • Learn About Treatments in Development
  • Research
    • Research Approach
    • Research Projects We Fund
    • Research Pipeline
    • Gene Therapy
    • Clinical Trials
    • —-
    • Apply for Funding
    • Emerging Researcher Award
  • News & Stories
    • News
    • CMT Stories
  • Take Action
  • About Us
    • Who We Are
    • Board of Directors
    • Research Advisory Council
    • Scientific Advisory Board
    • Research Foundation Staff
    • Events
    • Financials
    • Contact Us
    • Velocity
    • Global CMT Research Convention
  • Donate

Are We Prepared for Clinical Trials in Charcot-Marie-Tooth?

Jan 7, 2020 | CMT Research Updates, Research News

A Review of Clinical Trial Readiness for CMT BY CMT RESEARCH FOUNDATION’S SCIENTIFIC ADVISORY BOARD MEMBER DR. ALEXANDER ROSSOR Read the full paper In this issue of Brain Research, Mike Shy, Mary Reilly and I summarize the current array of outcome measures for...

2019 – A Year of Closing the Gaps in CMT Drug Development

Dec 31, 2019 | Foundation News

Because of you, the pace of drug development for CMT accelerated! As we close the books on 2019, I am excited to share the progress the CMT Research Foundation has made this year.  Because of you, these advancements were possible. We have grown considerably in the...
Partnership with DTx Pharma to optimize antisense oligonucleotides as a gene therapy for CMT1A

Partnership with DTx Pharma to optimize antisense oligonucleotides as a gene therapy for CMT1A

Dec 20, 2019 | CMT Research Updates, CMTRF Funded Research, Research News

ATLANTA (December 20, 2019) The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company breaking open new therapeutic areas for...

Where is the Progress? The Cure For CMT Calls For Collaboration

Oct 11, 2019 | CMT Research Updates, Foundation News, Research News

More collaboration within the CMT research and patient community would help us get to treatments and a cure much faster. Thomas Durcan, an Assistant Professor for neurodegenerative disorders at McGill University recently wrote a very interesting appeal for...

AcuraStem Achieves First Milestone

Sep 18, 2019 | CMT Research Updates, Foundation News, Research News

Just nine months ago, we announced a milestone-based, research collaboration with AcuraStem to test thousands of compounds aimed at producing effective treatments for CMT2A. We are very pleased to report that AcuraStem has completed phase one of the CMT2A project. To...
« Older Entries
Next Entries »

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Foundation News
  • Life with CMT
  • Research News

Help us find a cure.

Donate Now
Donate Now

Help us find a cure.

NEWSLETTER SIGNUP

Stay up to date on new CMT research, treatments and clinical trials



Address

4062 Peachtree Road
Suite A209
Atlanta, GA 30319



Phone Number

404.806.7180



EMAIL

[email protected]

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2025 CMT Research Foundation | Privacy Policy

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}